We identified that depletion of both KDM3A and KDM4B together has a greater inhibitory effect on both ER-target gene expression and BC cell growth than targeting either enzyme individually, suggesting that dual targeting of KDM3A and KDM4B may have significant clinical applications in ER-positive BC. Here, KDM4B is linked to breast cancer.